It is well accepted that the prophylactic administration of 5-hydroxytryptamine type-3 (5-HT 3 ) receptor antagonists, such as granisetron and ondansetron, has provided a de®nite clinical advance in the treatment of early vomiting induced by either chemo-or radiotherapy. 1 Indeed, physicians and nurses have noted that treatment with 5-HT 3 antagonists contributes to an increased quality of life and to patient compliance with the often distressing anticancer treatment protocols. 2 Ondansetron and granisetron are well tolerated, have a good oral bioavailability 3 and the pharmacodynamic effects appear to last longer than the pharmacokinetic data suggest. 4,5 One notable sideeffect often reported following treatment with these 5-HT 3 antagonists is constipation. 2 This is perhaps of clinical relevance as diarrhoea is also a frequent sequel to radiotherapy of the abdominal region, which may occur acutely during treatment and be related to the release of mediators such as 5-HT as well as to epithelial injury. 6 Indeed, Henriksson et al. have suggested that SUMMARY Background: Radiation-induced diarrhoea is attributed to both mucosal injury and alterations of intestinal motility. Previous reports have indicated that 5-hydroxytryptamine is released following irradiation, which may contribute to these changes. Aims: To investigate the effects of granisetron (5-hydroxytryptamine type-3 receptor antagonist) on colonic motility,¯uid absorption and 5-hydroxytryptamine colonic content following abdominal irradiation (10 Gy) in rats. Methods: In vivo measurements of motility and¯uid absorption in the proximal and distal colon, respectively, diarrhoea score and 5-hydroxytryptamine tissue levels were performed 3 and 7 days after abdominal irradiation. The effects of post-irradiation granisetron (0.3 mg/kg subcutaneously) were also evaluated.